Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA

Rank in Stocks #19388
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.26
Last synced: 2026-11-18
Market Cap
$101.72M
Change (1 day)
-0.61%
Change (1 year)
-33.83%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
P/S ratio for Heidelberg Pharma AG (HPHA)
P/S ratio as of November 2026 TTM: 10.49
According to Heidelberg Pharma AG's latest financial reports and stock price, its current price-to-sales ratio (TTM) is 10.49. At the end of 2025 the company had a P/S ratio of 92.22.
P/S ratio history for Heidelberg Pharma AG from 2006 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 10.49 -88.62%
2025 92.22 464.73%
2024 16.33 25.19%
2023 13.04 13.39%
2022 11.50 -88.04%
2021 96.22 425.35%
2020 18.32 114.73%
2019 8.53 -60.95%
2018 21.84 5.77%
2017 20.65 -45.90%
2016 38.17 470.94%
2015 6.69 46.81%
2014 4.55 31.04%
2013 3.48 127.52%
2012 1.53 -96.38%
2011 42.20 0.00%
2010 0.00 -100.00%
2009 6.51 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.51 0.19%
US
35.79 241.12%
US
4.19 -60.07%
AU
6.63 -36.80%
BE
13.60 29.59%
NL

Questions about Heidelberg Pharma AG's P/S ratio

What is Heidelberg Pharma AG's P/S ratio?

Heidelberg Pharma AG's P/S ratio is 10.49, as of Nov 2026.

What was Heidelberg Pharma AG's P/S ratio in 2025?

In 2025, Heidelberg Pharma AG's P/S ratio was 92.22, compared with 16.33 in 2024.

How has Heidelberg Pharma AG's P/S ratio changed since 2020?

From 2020 to 2025, Heidelberg Pharma AG's P/S ratio was highest in 2021 (96.22) and lowest in 2022 (11.50).

How does Heidelberg Pharma AG's P/S ratio compare with similar companies?

Heidelberg Pharma AG's P/S ratio (10.49) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.